Tirzepatide in type 1 diabetes: cardiometabolic effects (TIRTLE)

Cardiovascular disease and its risk factors are prominent issues in type 1 diabetes. There is a need to identify treatments that can address weight, blood sugar management and heart disease risk factors in type 1 diabetes. Tirzepatide is a medication usually used in type 2 diabetes. Whether tirzepatide improves health in type 1 diabetes has not been studied before. The TIRTLE study is a clinical trial studying the effect of tirzepatide on weight and metabolism in adults with type 1 diabetes.

Treatment

The study medication in this trial is given by injection into the skin once a week for 12 weeks. For every 2 participants, 1 will receive the study medication, and 1 will receive placebo. The allocation of medication is done randomly.

Benefits of participation

In addition to improving knowledge about weight management and metabolic health in type 1 diabetes, test results such as body composition measurements will be shared with you.

There is no cost to participate in the study.

Contact

Email: TIRTLE@garvan.org.au

Phone: 0491 731 769